Skip to content
Despite women making up half the population, women’s health has historically been “woefully underfunded,” accounting for less than 5% of products in the biotech […]
Women’s History Month: What’s the story with women’s health investment? Read More »
Patient perspectives are vital to inform health policy. One agency where such input is particularly crucial is the Centers for Medicare and Medicaid Services
Patient organization engagement of CMS is more important than ever Read More »
Biotechnology and agriculture have evolved together. Since humanity first started farming, we have been working to impact soil, plants, animals, and microbes to secure
National Agriculture Day: Biotech and agriculture grow together Read More »
The Food and Drug Administration’s (FDA) Rare Pediatric Disease Priority Review Voucher (PPRV) Program was top of mind during BIO’s March Patient Advocacy Coffee
Whether it’s bottles, baby wipes, fashion, or fuel, biology can build it better. Biobased products, made from renewable natural materials, provide sustainable alternatives to
National Biobased Products Day: Building better with biology Read More »
March 8th is International Women’s Day and to mark the occasion, Bio.News is exploring an under researched field of women’s health – autoimmune diseases
International Women’s Day: Improving women’s health by addressing autoimmune disease Read More »
The time has come for Congress to pass legislation to prevent pharmacy benefit managers (PBMs) from inflating drug costs, limiting patient access to drugs,
House members urge passage of reforms at PBM hearing Read More »
Bipartisan legislation reintroduced in the House on Feb. 21 would encourage the development of small-molecule drugs by eliminating the “pill penalty” in the Inflation
EPIC Act introduced to correct IRA’s ‘pill penalty’ Read More »
“Kidney disease is a major and growing public health concern,” LaVarne A. Burton, American Kidney Fund President and CEO, said in an interview with
Kidney Action Week: 4 things you need to know about kidney disease Read More »
The Centers for Medicare & Medicaid Services (CMS) recently announced the 2025 selection of 15 drugs covered under Medicare Part D for price “negotiations”
The role of the patient voice in CMS drug price ‘negotiation’ Read More »
